SHANGHAI, Dec. 15, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, announced that it will open offices in Boston and San Francisco in early 2015. These new offices will give the company greater access to innovative companies in the world's two leading biotech hubs, both as customers and as investments. In October, WuXi announced that it had opened an office in Israel to tap into the biotech community there. In addition, the company has U.S. facilities in St. Paul, Philadelphia, Atlanta, Plainsboro (NJ), and San Diego.
"Our vision is to enable anyone and any company to discover and develop healthcare products to benefit the world's patients," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "These new offices bring our comprehensive platform of integrated R&D services closer to where entrepreneurs are and where cutting-edge science is being done."
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact:
Director of Investor Relations
+1 (201) 585-2048
Director of Corporate Communications
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wuxi-opening-offices-in-boston-and-san-francisco-300009394.html
SOURCE WuXi PharmaTech (Cayman) Inc.